Peter Nolan-World Wide President, BD Medical Pharmaceutical Systems
-
- Peter Nolan-World Wide President, BD Medical Pharmaceutical Systems's presentations
BD is a Fortune 500 Company with Corporate Headquarters in Franklin Lakes, New Jersey, USA, with Revenue in 2017 of USD12Bn. BD Medical -Pharmaceutical Systems is one of eight Business Units within BD, and is headquartered near Grenoble in France. As World Wide President of BDM-PS, Peter also serves as a member of the overall BD Leadership Team.
Peter joined BD in December, 2012 from Safety Syringes, Inc. San Diego, California, where he was President and Chief Executive Officer. Peter was a semi-finalist in the 2011 E&Y Entrepreneur of the year Award for San Diego, California, having led SSI through a transformation in manufacturing, product development, strategic marketing, commercial development and customer service strategy. Under Peter’s leadership, this business significantly improved its revenue growth, enhanced operations and increased the value of its new product pipeline.
Peter has extensive experience in global business management and operations, and has held Corporate Vice President of Global Operations roles in Advanced Medical Optics (now part of J&J) and GN ReSound, leading teams in USA, Europe and Asia, implementing growth strategies, lean & six sigma methodologies, turnarounds, and supply chain & value stream optimization.
Peter holds a B.Sc. in Engineering and an Honorary Masters in Philosophy from the University Of Limerick, Ireland.Presentation Title- Leading with Excellence in Customer Experience -Operations Excellence as an Enabler.
Presentation Synopsis-
-BD Medical – Pharmaceutical Systems provides innovative design and technology, regulatory knowledge, product development expertise and highly capable support and services. With more than 30 years of experience in the pre-fillable injectable syringe markets, BDM – PS has the necessary resources to support our customers throughout their therapeutic drugs’ lifecycle, from development to launch and beyond.-Assurance of business continuity, and a highly flexible supply chain are critical to our customer’s success. Over the years BD has been moving toward meeting these expectations through continuous improvement processes so that our customers can provide therapeutic doses everywhere in the world.
-In recent years we have initiated, in collaboration with our customers, a major transformation effort aiming at optimizing our plants network, deploying new technologies and re-engineering key processes such as the End to End supply chain to improve our assurance of supply.
– Improving overall product quality is a must in the highly regulated healthcare industry where the quality expectations have dramatically increased in recent years. We have developed and are deploying state-of-the art new manufacturing technology in order to achieve this goal.
– We have been redesigning our processes in order to shorten our response to our customers in particular during the drug development stage to accelerate their time to market. In particular we have developed a center-of-excellence for R&D and process engineering piloting.
– As a result of this collaborative effort we have seen significant reduction of lead time in our supply chain and have improved overall quality standards and the customer experience
Similar Speakers
